A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months

Background and study aims: Obesity is a major public health problem with few effective treatment options. A novel device for treating obesity, the AspireAssist aspiration therapy system, was evaluated.

Patients and methods: After 4 weeks taking a very-low-calorie diet, 25 obese men and women (BMI 39.8 ± 0.9 kg/m²) had the AspireAssist gastrostomy tube placed during a gastroscopy. A low-profile valve was installed 14 days later and aspiration of gastric contents was performed approximately 20 minutes after meals three times per day. Cognitive behavioral therapy was also started.

Results: At month 6, mean weight lost was 16.5 ± 7.8 kg in the 22 subjects who completed 26 weeks of therapy (P = 0.001). The mean percentage excess weight lost was 40.8 ± 19.8 % (P = 0.001). Two subjects were hospitalized for complications: one subject for pain after gastrostomy tube placement, which was treated with analgesics, and another because of an aseptic intra-abdominal fluid collection 1 day after gastrostomy tube placement. No clinically significant changes in serum potassium or other electrolytes occurred.

Conclusion: In this study, substantial weight loss was achieved with few complications using the AspireAssist system, suggesting its potential as an attractive therapeutic device for obese patients.

Trial Register ISRCTN 49958132.

• References

• 1 Poirier P, Giles TD, Bray GA et al. Activity, obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight and metabolism loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918
• 2 Sjöström L, Narbro K, Sjöström CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. NEJM 2007; 357: 741-752
• 3 Sullivan S, Stein R, Jonnalagadda S et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013; 145: 1245-1252
• 4 Blomberg J, Lagergren P, Martin L et al. Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomized controlled trial. BMJ 2010; 341: c3115
• 5 Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-1575
• 6 Carlin AM, Zeni TM, English WJ et al. The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity. Ann Surg 2013; 257: 791-797
• 7 Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2008; 4: 47-S55
• 8 Ballesteros P, Diez RR, Calleja FA et al. Effects of preoperative weight loss with a very low calorie diet (VLCD) on weight loss after biliopancreatic diversion in patients with severe obesity. Nutr Hosp 2013; 28: 71-77
• 9 Cassie S, Menezes C, Birch DW et al. Effect of preoperative weight loss in bariatric surgical patients: a systematic review. Surg Obes Relat Dis 2011; 7: 760-767 ; discussion 767
• 10 Blomberg J, Lagergren J, Martin L et al. Complications after percutaneous endoscopic gastrostomy in a prospective study. Scand J Gastroenterol 2012; 47: 737-742
• 11 Gennari FJ. Pathophysiology of metabolic alkalosis: a new classification based on the centrality of stimulated collecting duct ion transport. Am J Kidney Dis 2011; 58: 626-636